Early results from the company’s single-arm trial saw the therapy able to partially repair the chemical responsible for ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Toddlers who were born with the most severe form of childhood blindness can now see after groundbreaking gene therapy ...

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.35 per share a year ago.

Four children born with a rare genetic form of severe blindness have all experienced significant improvements in their ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4 ...

Hyderabad: Cell and gene therapy solutions provider Miltenyi Biotec on Monday announced the roll-out of what is touted as ...

CompareNetworks is proud to announce the publication of the first issue of Cell & Gene Therapy Review, marking a significant ...